Association Between Inherited CYP2D6/2C19 Phenotypes and Anticholinergic Measures in Elderly Patients Using Anticholinergic Drugs

摘要: Background: To compare measures of anticholinergic activity between metabolic phenotypes the polymorphic enzymes cytochrome P450 2D6 (CYP2D6) and CYP2C19 in elderly patients exposed to agents. Methods: Long-term nursing home (n = 80) with an drug scale (ADS) score $3 were recruited from 22 homes Norway. Based on pharmacogenetic analyses mutations encoding absent CYP2D6 or metabolism, divided into subgroups poor metabolizers (PMs) 8) extensive 72). Serum (SAA) was determined by a validated, 96-well format radio receptor assay adjusted for ADS score. Unadjusted SAAs, mouth dryness, cognitive function (Mini-Mental State Examination verbal recall tests Consortium Establish Registry Alzheimer Disease) compared Mann–Whitney tests. Results: The study population represented 78% women, 68% had mild moderate dementia, mean age 86 years. More than 80% used more 1 agent, their median 4. subpopulation PMs significantly higher SAA (10.3 versus 4.2 pmol atropine equivalents per milliliter, P 0.012). This difference remained significant after adjusting (P 0.013). No differences dryness observed . 0.3). Conclusions: These preliminary findings suggest that CYP2D6/CYP2C19 high burden are at increased risk elevated SAA. Whether also prone experience side effects needs be further studied larger patient populations.